Spotlight

UCL cancer immunotherapy company, Autolus, launches with £30m investment

A new UCL spin-out company – Autolus – is being launched today to develop and commercialise a new generation of engineered T-cell therapies for haematological and solid tumours, with the backing of £30m in investment from healthcare investment company Syncona.

Find out more



follow us on twitter


UCL, Intel and Imperial poised to establish Institute for Sustainable Connected Cities

19 January 2012

UCL, Imperial College London and Intel have signed a Memorandum of Understanding (MoU) with the aim of establishing an Institute for Sustainable Connected Cities. Read more...